{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T03:35:48Z","timestamp":1789529748350,"version":"build-2803163510"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"am","delay-in-days":350,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["R01 HD093612"],"award-info":[{"award-number":["R01 HD093612"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemico-Biological Interactions"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.cbi.2022.110097","type":"journal-article","created":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T10:57:09Z","timestamp":1660215429000},"page":"110097","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["In vitro evaluation of the impact of Covid-19 therapeutic agents on the hydrolysis of the antiviral prodrug remdesivir"],"prefix":"10.1016","volume":"365","author":[{"given":"Qingchen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8276-6621","authenticated-orcid":false,"given":"Philip W.","family":"Melchert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Markowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.cbi.2022.110097_bib1","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00221-18","article-title":"Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease","volume":"9","author":"Agostini","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.cbi.2022.110097_bib2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s15010-020-01557-7","article-title":"Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence","volume":"49","author":"Lin","year":"2021","journal-title":"Infection"},{"key":"10.1016\/j.cbi.2022.110097_bib3","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/cts.12840","article-title":"Safety, tolerability, and pharmacokinetics of remdesivir, an antiviral for treatment of COVID-19, in healthy subjects","volume":"13","author":"Humeniuk","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.cbi.2022.110097_bib4","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s40262-021-00984-5","article-title":"Pharmacokinetic, pharmacodynamic, and drug-interaction profile of remdesivir, a SARS-CoV-2 replication inhibitor","volume":"60","author":"Humeniuk","year":"2021","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.cbi.2022.110097_bib5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.5582\/ddt.2020.03097","article-title":"Analytical methods for the determination of remdesivir as a promising antiviral candidate drug for the COVID-19 pandemic","volume":"14","author":"Pashaei","year":"2021","journal-title":"Drug Discov. Ther."},{"key":"10.1016\/j.cbi.2022.110097_bib6","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41397-021-00209-9","article-title":"Pharmacogenomics and COVID-19: clinical implications of human genome interactions with repurposed drugs","volume":"21","author":"Badary","year":"2021","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.cbi.2022.110097_bib7","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13557","article-title":"Non-steroidal anti-inflammatory drugs in management of COVID-19; A systematic review on current evidence","volume":"74","author":"Yousefifard","year":"2020","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.cbi.2022.110097_bib8","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0090-9556(24)15182-3","article-title":"An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation","volume":"28","author":"Mayhew","year":"2000","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cbi.2022.110097_bib9","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1007\/s11095-011-0637-9","article-title":"Prediction and in vitro evaluation of selected protease inhibitor antiviral drugs as inhibitors of carboxylesterase 1: a potential source of drug-drug interactions","volume":"29","author":"Rhoades","year":"2012","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.cbi.2022.110097_bib10","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/ADM.0000000000000771","article-title":"COVID-19 and cannabidiol (CBD)","volume":"15","author":"Khalsa","year":"2021","journal-title":"J. Addiction Med."},{"issue":"4","key":"10.1016\/j.cbi.2022.110097_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22041986","article-title":"Opportunities, challenges and pitfalls of using cannabidiol as an adjuvant drug in COVID-19","volume":"22","author":"Malinowska","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cbi.2022.110097_bib12","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1124\/dmd.118.086074","article-title":"In vitro inhibition of carboxylesterase 1 by major cannabinoids and selected metabolites","volume":"47","author":"Qian","year":"2019","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cbi.2022.110097_bib13","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.ajhg.2008.04.015","article-title":"Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis","volume":"82","author":"Zhu","year":"2008","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.cbi.2022.110097_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FPC.0b013e32835aa8a2","article-title":"The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response","volume":"23","author":"Lewis","year":"2013","journal-title":"Pharmacogenetics Genom."},{"key":"10.1016\/j.cbi.2022.110097_bib15","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s40262-014-0160-3","article-title":"Physiologically based pharmacokinetic modeling of impaired carboxylesterase-1 activity: effects on oseltamivir disposition","volume":"53","author":"Hu","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.cbi.2022.110097_bib16","article-title":"Human carboxylesterase 1A plays a predominant role in the hydrolytic activation of remdesivir in humans","volume":"351","author":"Zhang","year":"2021","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.cbi.2022.110097_bib17","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s12325-020-01566-w","article-title":"Metabolic effects of aripiprazole and olanzapine multiple-dose treatment in a randomised crossover clinical trial in healthy volunteers: association with pharmacogenetics","volume":"38","author":"Koller","year":"2021","journal-title":"Adv. Ther."},{"issue":"Suppl 1","key":"10.1016\/j.cbi.2022.110097_bib18","doi-asserted-by":"crossref","first-page":"57S","DOI":"10.1046\/j.1365-2125.2000.00154.x","article-title":"The pharmacokinetics of ziprasidone in healthy volunteers treated with cimetidine or antacid","volume":"49","author":"Wilner","year":"2000","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.cbi.2022.110097_bib19","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.forsciint.2011.04.010","article-title":"A preliminary investigation on the distribution of cannabinoids in man","volume":"210","author":"Gronewold","year":"2011","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.cbi.2022.110097_bib20","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s40263-018-0578-5","article-title":"A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects","volume":"32","author":"Taylor","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.cbi.2022.110097_bib21","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.clml.2020.06.022","article-title":"Comparative safety, bioavailability, and pharmacokinetics of oral dexamethasone, 4-mg and 20-mg tablets, in healthy volunteers under fasting and fed conditions: a randomized open-label, 3-way crossover study","volume":"20","author":"Bashir","year":"2020","journal-title":"Clin. Lymphoma, Myeloma & Leukemia"},{"issue":"Suppl","key":"10.1016\/j.cbi.2022.110097_bib22","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/infdis\/128.Supplement_3.S547","article-title":"Pharmacokinetic profile of trimethoprim-sulfamethoxazole in man","volume":"128","author":"Kaplan","year":"1973","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.cbi.2022.110097_bib23","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1208\/s12248-007-9000-9","article-title":"The pharmacokinetics and interactions of ivermectin in humans--a mini-review","volume":"10","author":"Gonz\u00e1lez Canga","year":"2008","journal-title":"AAPS J."},{"key":"10.1016\/j.cbi.2022.110097_bib24","doi-asserted-by":"crossref","first-page":"370","DOI":"10.2165\/00003088-199325050-00003","article-title":"Azithromycin clinical pharmacokinetics","volume":"25","author":"Lalak","year":"1993","journal-title":"Clin. Pharmacokinet."},{"issue":"Suppl A","key":"10.1016\/j.cbi.2022.110097_bib25","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/jac\/25.suppl_A.73","article-title":"The pharmacokinetics of azithromycin in human serum and tissues","volume":"25","author":"Foulds","year":"1990","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.cbi.2022.110097_bib26","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00003088-199937050-00003","article-title":"Clinical pharmacokinetics of clarithromycin","volume":"37","author":"Rodvold","year":"1999","journal-title":"Clin. Pharmacokinet."},{"issue":"Suppl 1","key":"10.1016\/j.cbi.2022.110097_bib27","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1007\/BF01650500","article-title":"Pharmacokinetics of ciprofloxacin","volume":"16","author":"Bergan","year":"1988","journal-title":"Infection"},{"key":"10.1016\/j.cbi.2022.110097_bib28","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/BF01639131","article-title":"Pharmacokinetics and biological availability of erythromycin","volume":"5","author":"Chun","year":"1977","journal-title":"Infection"},{"key":"10.1016\/j.cbi.2022.110097_bib29","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/j.1552-4604.1988.tb05738.x","article-title":"Pharmacokinetics of roxithromycin (RU 965)","volume":"28","author":"Lassman","year":"1988","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.cbi.2022.110097_bib30","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/clpt.1983.225","article-title":"Vancomycin kinetics during continuous ambulatory peritoneal dialysis","volume":"34","author":"Bunke","year":"1983","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.cbi.2022.110097_bib31","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/cpt.1993","article-title":"Pharmacokinetics and pharmacological properties of chloroquine and hydroxychloroquine in the context of COVID-19 infection","volume":"108","author":"Nicol","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.cbi.2022.110097_bib32","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.5212","article-title":"Accelerated stability study of the ester prodrug remdesivir: recently FDA-approved Covid-19 antiviral using reversed-phase-HPLC with fluorimetric and diode array detection","volume":"35","author":"Hamdy","year":"2021","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.cbi.2022.110097_bib33","series-title":"Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems","first-page":"170","author":"Segel","year":"2014"},{"key":"10.1016\/j.cbi.2022.110097_bib34","doi-asserted-by":"crossref","first-page":"8264","DOI":"10.1021\/bi201284u","article-title":"The original Michaelis constant: translation of the 1913 Michaelis-Menten paper","volume":"50","author":"Michaelis","year":"2011","journal-title":"Biochemistry"},{"key":"10.1016\/j.cbi.2022.110097_bib35","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1208\/s12248-013-9554-7","article-title":"Use of different parameters and equations for calculation of IC\u2085\u2080 values in efflux assays: potential sources of variability in IC\u2085\u2080 determination","volume":"16","author":"Volpe","year":"2014","journal-title":"AAPS J."},{"key":"10.1016\/j.cbi.2022.110097_bib36","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.2042-7158.2010.01202.x","article-title":"Mechanism of cytochrome P450-3A inhibition by ketoconazole","volume":"63","author":"Greenblatt","year":"2011","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.cbi.2022.110097_bib37","series-title":"Drug\u2013Drug Interactions in Pharmaceutical Development","first-page":"31","article-title":"In vitro approaches to anticipating clinical drug interactions","author":"Volak","year":"2007"},{"key":"10.1016\/j.cbi.2022.110097_bib38","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/BF01059791","article-title":"Kinetics of drug-drug interactions","volume":"1","author":"Rowland","year":"1973","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"10.1016\/j.cbi.2022.110097_bib39","first-page":"131","article-title":"Mechanism of dasabuvir inhibition of acetaminophen glucuronidation","author":"Zhang","year":"2021","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.cbi.2022.110097_bib40","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.tox.2010.01.009","article-title":"Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions","volume":"270","author":"Zhu","year":"2010","journal-title":"Toxicology"},{"key":"10.1016\/j.cbi.2022.110097_bib41","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00228-012-1350-2","article-title":"Carboxylesterase 1 (CES1) genetic polymorphisms and oseltamivir activation","volume":"69","author":"Zhu","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.cbi.2022.110097_bib42","article-title":"Cannabidiol inhibits SARS-CoV-2 replication and promotes the host innate immune response","author":"Nguyen","year":"2021","journal-title":"BioRxiv [Preprint]"},{"key":"10.1016\/j.cbi.2022.110097_bib43","article-title":"Cannabidiol for COVID-19 patients with mild to moderate symptoms (candidate study): a randomized, double-blind, placebo-controlled clinical trial","author":"Crippa","year":"2021","journal-title":"Cannabis Cannabinoid. Res."},{"key":"10.1016\/j.cbi.2022.110097_bib44","article-title":"Cannabidiol inhibits in vitro human liver microsomal metabolism of remdesivir: a promising adjuvant for COVID-19 treatment","author":"Saraswat","year":"2021","journal-title":"Cannabis Cannabinoid. Res."},{"key":"10.1016\/j.cbi.2022.110097_bib45","doi-asserted-by":"crossref","first-page":"488","DOI":"10.5937\/jomb0-26725","article-title":"Pharmacogenomics landscape of COVID-19 therapy response in Serbian population and comparison with worldwide populations","volume":"39","author":"Stankovi\u0107","year":"2020","journal-title":"J. Med. Biochem."},{"key":"10.1016\/j.cbi.2022.110097_bib46","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41525-020-00143-y","article-title":"Pharmacogenomics of COVID-19 therapies","volume":"5","author":"Takahashi","year":"2020","journal-title":"NPJ Genom. Med."},{"key":"10.1016\/j.cbi.2022.110097_bib47","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1111\/cts.12989","article-title":"Impact of carboxylesterase 1 genetic polymorphism on trandolapril activation in human liver and the pharmacokinetics and pharmacodynamics in healthy volunteers","volume":"14","author":"Wang","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.cbi.2022.110097_bib48","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/phar.2429","article-title":"Remdesivir: review of pharmacology, pre-clinical data, and emerging clinical experience for COVID-19","volume":"40","author":"Jorgensen","year":"2020","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cbi.2022.110097_bib49","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01117-21","article-title":"Why remdesivir failed: preclinical assumptions overestimate the clinical efficacy of remdesivir for COVID-19 and ebola","volume":"65","author":"Yan","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.cbi.2022.110097_bib50","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2187","article-title":"Efficacy and safety of remdesivir in hospitalized Covid-19 patients: systematic review and meta-analysis including network meta-analysis","volume":"31","author":"Elsawah","year":"2021","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.cbi.2022.110097_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2021.02.013","article-title":"Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns","author":"Touafchia","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.cbi.2022.110097_bib52","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/cpt.2145","article-title":"Remdesivir and acute renal failure: a potential safety signal from disproportionality analysis of the WHO safety database","volume":"109","author":"G\u00e9rard","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.cbi.2022.110097_bib53","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.705","article-title":"Drug-drug interactions with candidate medications used for COVID-19 treatment: an overview","volume":"9","author":"Rezaee","year":"2021","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.cbi.2022.110097_bib54","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01920-20","article-title":"Captisol and GS-704277, but not GS-441524, are credible mediators of remdesivir's nephrotoxicity","volume":"64","author":"Yan","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.cbi.2022.110097_bib55","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00602-21","article-title":"Key metabolic enzymes involved in remdesivir activation in human lung cells","volume":"65","author":"Li","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.cbi.2022.110097_bib56","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1124\/dmd.119.089680","article-title":"Carboxylesterase 1 and precision pharmacotherapy: pharmacogenetics and nongenetic regulators","volume":"48","author":"Her","year":"2020","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cbi.2022.110097_bib57","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s13318-020-00668-8","article-title":"Potential effects of COVID-19 on cytochrome P450-mediated drug metabolism and disposition in infected patients","volume":"46","author":"Deb","year":"2021","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.cbi.2022.110097_bib58","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/cts.12815","article-title":"What do we know about remdesivir drug interactions?","volume":"13","author":"Yang","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.cbi.2022.110097_bib59","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.2165\/11317010-000000000-00000","article-title":"Interactions between herbal medicines and prescribed drugs: an updated systematic review","volume":"69","author":"Izzo","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.cbi.2022.110097_bib60","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2165\/00003088-200544030-00005","article-title":"Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs","volume":"44","author":"Zhou","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.cbi.2022.110097_bib61","first-page":"1053","article-title":"Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin","volume":"26","author":"Yamazaki","year":"1998","journal-title":"Drug Metab. Dispos."}],"container-title":["Chemico-Biological Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279722003027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279722003027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T14:13:31Z","timestamp":1757859211000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009279722003027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":61,"alternative-id":["S0009279722003027"],"URL":"https:\/\/doi.org\/10.1016\/j.cbi.2022.110097","relation":{},"ISSN":["0009-2797"],"issn-type":[{"value":"0009-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro evaluation of the impact of Covid-19 therapeutic agents on the hydrolysis of the antiviral prodrug remdesivir","name":"articletitle","label":"Article Title"},{"value":"Chemico-Biological Interactions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbi.2022.110097","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110097"}}